Anika Therapeutics Inc (ANIK) is a publicly traded Healthcare sector company. As of May 21, 2026, ANIK trades at $15.50 with a market cap of $198.92M and a P/E ratio of -19.92. ANIK moved +1.48% today. Year to date, ANIK is +59.87%; over the trailing twelve months it is +26.59%. Its 52-week range spans $7.87 to $25.65. Analyst consensus is buy with an average price target of $17.50. Rallies surfaces ANIK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Anika Therapeutics Q1 Revenue $29.6M, 35% Integrity Growth and 64% Margin: Anika Therapeutics reported Q1 revenue of $29.6M with a GAAP loss of $5.1M (-37c EPS) and adjusted EPS of $0.27. Commercial channel revenue rose 12% overall and 35% in U.S. Integrity procedures, supporting a 64% gross margin as management targets expansion beyond 92% of rotator cuff cases.
| Metric | Value |
|---|---|
| Price | $15.50 |
| Market Cap | $198.92M |
| P/E Ratio | -19.92 |
| EPS | $-0.76 |
| Dividend Yield | 0.00% |
| 52-Week High | $25.65 |
| 52-Week Low | $7.87 |
| Volume | 7 |
| Avg Volume | 0 |
| Revenue (TTM) | $112.82M |
| Net Income | $-10.88M |
| Gross Margin | 56.56% |
2 analysts cover ANIK: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $17.50.